Published in Br J Clin Pharmacol on October 01, 2002
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 4.36
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 3.69
Pharmacogenetic prediction of clozapine response. Lancet (2000) 3.10
Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet (1995) 3.08
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry (1998) 3.07
The genetic basis of complex human behaviors. Science (1994) 2.62
A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A (1995) 1.91
Dopamine D4 receptor subtypes and response to clozapine. Lancet (1993) 1.69
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry (1997) 1.53
The role of serotonin in antipsychotic drug action. Neuropsychopharmacology (1999) 1.49
Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry (2000) 1.30
Pharmacogenetics of the clozapine response. Lancet (2000) 1.17
Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res (1998) 1.05
The evolution of drug metabolism. Pharmacology (2000) 1.03
Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology (1998) 0.99
Limbic selectivity of clozapine. Lancet (1997) 0.93
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol (1999) 0.91
Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry (1998) 0.88
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology (1999) 0.88
The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics (2000) 0.88
Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry (2000) 0.88
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry (1999) 0.87
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol (1999) 0.87
Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport (1995) 0.86
Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry (1997) 0.86
The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol (2000) 0.86
Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett (1996) 0.85
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics (2000) 0.82
Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology (1996) 0.81
Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol (1997) 0.81
Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) (1999) 0.79
Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Mol Psychiatry (2001) 0.78
Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet (1995) 0.78
Analysis of the conserved Asp(114) residue of the dopamine D2 receptor in schizophrenic patients. Psychiatr Genet (1994) 0.76
Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry (2006) 1.57
Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology (2004) 1.32
Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol (2011) 1.23
The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry (2004) 1.21
Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs (2003) 1.15
Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol (2003) 1.04
Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol (2005) 1.01
The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology (2003) 1.01
A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol Psychiatry (2002) 1.01
Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics (2008) 0.99
Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. J Psychopharmacol (2012) 0.99
Association of the dysbindin gene with bipolar affective disorder. Am J Psychiatry (2006) 0.91
Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter (2005) 0.90
Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) (2004) 0.87
Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) (2002) 0.84
Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res (2002) 0.82
Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. Schizophr Res (2005) 0.82
Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry (2005) 0.79
Pharmacogenomics of psychiatric drug treatment. Curr Opin Mol Ther (2003) 0.79
Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs (2002) 0.79
An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol (2008) 0.79
Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.78
Expression of the alpha1A-adrenergic receptor in schizophrenia. Neurosci Lett (2006) 0.75